全文获取类型
收费全文 | 328篇 |
免费 | 30篇 |
国内免费 | 29篇 |
专业分类
儿科学 | 14篇 |
妇产科学 | 1篇 |
基础医学 | 24篇 |
口腔科学 | 25篇 |
临床医学 | 44篇 |
内科学 | 67篇 |
皮肤病学 | 8篇 |
神经病学 | 18篇 |
特种医学 | 112篇 |
外科学 | 10篇 |
综合类 | 22篇 |
预防医学 | 3篇 |
药学 | 29篇 |
肿瘤学 | 10篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 3篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 6篇 |
2012年 | 4篇 |
2011年 | 5篇 |
2010年 | 6篇 |
2009年 | 11篇 |
2008年 | 5篇 |
2007年 | 14篇 |
2006年 | 5篇 |
2005年 | 18篇 |
2004年 | 4篇 |
2003年 | 6篇 |
2002年 | 9篇 |
2001年 | 8篇 |
2000年 | 2篇 |
1999年 | 7篇 |
1998年 | 22篇 |
1997年 | 25篇 |
1996年 | 21篇 |
1995年 | 8篇 |
1994年 | 25篇 |
1993年 | 23篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 5篇 |
1989年 | 19篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 4篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 12篇 |
1980年 | 4篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1976年 | 5篇 |
1975年 | 6篇 |
排序方式: 共有387条查询结果,搜索用时 15 毫秒
381.
Pleural thickening. An unusual feature of childhood leukemia 总被引:1,自引:0,他引:1
382.
383.
Craig M. Mcdonald MD Erik K. Henricson MPH R. Ted Abresch MS Julaine M. Florence PhD Michelle Eagle PhD Eduard Gappmaier PhD Allan M. Glanzman DPT PTC‐GD‐‐DMD Study Group Robert Spiegel MD Jay Barth MD Gary Elfring MS Allen Reha MS Stuart Peltz PhD 《Muscle & nerve》2013,48(3):343-356
Introduction: Duchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followed for 48 weeks in a multicenter, randomized, double‐blind, placebo‐controlled trial of ataluren. Placebo arm data (N = 57) provided insight into the natural history of the 6‐minute walk test (6MWT) and other endpoints. Methods: Evaluations performed every 6 weeks included the 6‐minute walk distance (6MWD), timed function tests (TFTs), and quantitative strength using hand‐held myometry. Results: Baseline age (≥7 years), 6MWD, and selected TFT performance are strong predictors of decline in ambulation (Δ6MWD) and time to 10% worsening in 6MWD. A baseline 6MWD of <350 meters was associated with greater functional decline, and loss of ambulation was only seen in those with baseline 6MWD <325 meters. Only 1 of 42 (2.3%) subjects able to stand from supine lost ambulation. Conclusion: Findings confirm the clinical meaningfulness of the 6MWD as the most accepted primary clinical endpoint in ambulatory DMD trials. Muscle Nerve 48 : 343–356, 2013 相似文献
384.
385.
386.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD 《Blood》1996,87(4):1495-1501
Osteolytic bone destruction and its complications, bone pain, pathologic fractures, and hypercalcemia, are a major source of morbidity and mortality in patients with multiple myeloma. The bone destruction in multiple myeloma is due to increased osteoclast (OCL) activity and decreased bone formation in areas of bone adjacent to myeloma cells. The mechanisms underlying osteolysis in multiple myeloma in vivo are unclear. We used a human plasma cell leukemia cell line, ARH-77, that has disseminated growth in mice with severe combined immunodeficiency (SCID) and expresses IgG kappa, as a model for human multiple myeloma, SCID mice were irradiated with 400 rads and mice were injected either with 10(6) ARH-77 cells intravenously (ARH-77 mice) or vehicle 24 hours after irradiation. Development of bone disease was assessed by blood ionized calcium levels, x-rays, and histology. All ARH-77, but none of control mice that survived irradiation, developed hind limb paralysis 28 to 35 days after injection and developed hypercalcemia (1.35 to 1.46 mmol/L) a mean of 5 days after becoming paraplegic. Lytic bone lesions were detected using x-rays in all the hypercalcemic mice examined. No lytic lesions or hypercalcemia developed in the controls. Controls or ARH-77 mice, after developing hypercalcemia, were then killed and bone marrow plasma from the long bones were obtained, concentrated, and assayed for bone-resorbing activity. Bone marrow plasma from ARH-77 mice induced significant bone resorption in the fetal rat long bone resorption assay when compared with controls (percentage of total 45Ca released = 35% +/- 4% v 11% +/- 1%). Histologic examination of tissues from the ARH-77 mice showed infiltration of myeloma cells in the liver and spleen and marked infiltration in vertebrae and long bones, with loss of bony trabeculae and increased OCL numbers. Interestingly, cultures of ARH-77 mouse bone marrow for early OCL precursors (colony-forming unit-granulocyte- macrophage [CFU-GM]) showed a threefold increase in CFU-GM from ARH-77 marrow versus controls (185 +/- 32 v 40 +/- 3 per 2 x 10(5) cell plated). Bone-resorbing human and murine cytokines such as interleukin- 6 (IL-6), IL-1 alpha or beta, TGF-alpha, lymphotoxin, and TNF alpha were not significantly increased in ARH-77 mouse sera or marrow plasma, compared with control mice, although ARH-77 cells produce IL-6 and lymphotoxin in vitro. Conditioned media from ARH-77 cells induced significant bone resorption in the fetal rat long bone resorption assay when compared with untreated media (percentage of total 45Ca released = 22% +/- 2% v 11% +/- 1%). This effect was not blocked by anti-IL-6 or antilymphotoxin (percentage of total 45Ca released = 19% +/- 1% and 22% +/- 1%, respectively). Thus, we have developed a model of human multiple myeloma bone disease that should be very useful to dissect the pathogenesis of the bone destruction in multiple myeloma. 相似文献
387.